长链非编码RNA GHET1在癌症中的预后价值：一项系统评价和荟萃分析。
Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis.
作者信息
Wang Dingding, Zhang Hong, Fang Xiaolian, Zhang Xue, Liu Honggang
机构信息
1Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730 China.
2Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No.56 Nanlishi Rd, Beijing, 100045 China.
出版信息
Cancer Cell Int. 2020 Apr 7;20:109. doi: 10.1186/s12935-020-01189-9. eCollection 2020.
BACKGROUND
A number of studies have demonstrated the critical role of long non-coding RNA gastric cancer high expressed transcript 1 (GHET1) in many cancers. This meta-analysis provides an evidence-based evaluation of the prognostic role of GHET1 in cancer.
MATERIALS AND METHODS
Literature searches were conducted in several databases including Medline, Cochrane, EMBASE, CNKI, and Wanfang. The pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (CI) were used to evaluate the role of GHET1 in cancer. The study protocol was registered at PROSPERO (ID: CRD42018111252).
RESULTS
Sixteen studies, containing 1315 patients, were analyzed in this meta-analysis. The pooled results indicated that GHET1 overexpression was significantly associated with poor overall survival (OS) and disease-free survival (DFS) in cancer. Moreover, up-regulation of GHET1 expression predicted larger tumor size, positive lymph node metastasis, positive distant metastasis, and advanced TNM (tumor-node-metastases) stage in human cancers.
CONCLUSION
There is a significant correlation between up-regulation of GHET1 and both poor prognosis and advanced clinicopathological cancer characteristics. GHET1 may be a potential prognostic predictor for human cancers.
背景
多项研究已证明长链非编码RNA胃癌高表达转录本1（GHET1）在多种癌症中起关键作用。本荟萃分析对GHET1在癌症中的预后作用进行了基于证据的评估。
材料与方法
在包括Medline、Cochrane、EMBASE、中国知网和万方在内的多个数据库中进行文献检索。采用合并比值比（OR）和风险比（HR）及95%置信区间（CI）来评估GHET1在癌症中的作用。该研究方案已在国际前瞻性系统评价注册库（PROSPERO）注册（注册号：CRD42018111252）。
结果
本荟萃分析纳入了16项研究，共1315例患者。汇总结果表明，GHET1过表达与癌症患者较差的总生存期（OS）和无病生存期（DFS）显著相关。此外，GHET1表达上调预示着人类癌症中肿瘤体积更大、淋巴结转移阳性、远处转移阳性以及肿瘤-淋巴结-转移（TNM）分期较晚。
结论
GHET1上调与预后不良及癌症临床病理特征进展均显著相关。GHET1可能是人类癌症潜在的预后预测指标。
Zotero 插件